CD137 Expression Is Induced by Epstein-Barr Virus Infection through LMP1 in T or NK Cells and Mediates Survival Promoting Signals
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
CD137 Expression Is Induced by Epstein-Barr Virus Infection through LMP1 in T or NK Cells and Mediates Survival Promoting Signals
Authors
Keywords
Epstein-Barr virus, Antibodies, NK cells, Cell staining, Protein expression, T cells, Flow cytometry, Reverse transcriptase-polymerase chain reaction
Journal
PLoS One
Volume 9, Issue 11, Pages e112564
Publisher
Public Library of Science (PLoS)
Online
2014-11-20
DOI
10.1371/journal.pone.0112564
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- CD137 Is Induced by the CD40 Signal on Chronic Lymphocytic Leukemia B Cells and Transduces the Survival Signal via NF-κB Activation
- (2013) Yukana Nakaima et al. PLoS One
- CD137 Is Expressed in Follicular Dendritic Cell Tumors and in Classical Hodgkin and T-Cell Lymphomas
- (2012) Matthew W. Anderson et al. AMERICAN JOURNAL OF PATHOLOGY
- EBV-associated T/NK-cell lymphoproliferative diseases in nonimmunocompromised hosts: prospective analysis of 108 cases
- (2011) H. Kimura et al. BLOOD
- Clinical features of adult-onset chronic active Epstein–Barr virus infection: a retrospective analysis
- (2011) Ayako Arai et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Phase II Study of SMILE Chemotherapy for Newly Diagnosed Stage IV, Relapsed, or Refractory Extranodal Natural Killer (NK)/T-Cell Lymphoma, Nasal Type: The NK-Cell Tumor Study Group Study
- (2011) Motoko Yamaguchi et al. JOURNAL OF CLINICAL ONCOLOGY
- CD40 Is Essential in the Upregulation of TRAF Proteins and NF-KappaB-Dependent Proinflammatory Gene Expression after Arterial Injury
- (2011) Zifang Song et al. PLoS One
- Novel Mouse Xenograft Models Reveal a Critical Role of CD4+ T Cells in the Proliferation of EBV-Infected T and NK Cells
- (2011) Ken-Ichi Imadome et al. PLoS Pathogens
- CD137 agonist antibody prevents cancer recurrence: contribution of CD137 on both hematopoietic and nonhematopoietic cells
- (2010) H. Narazaki et al. BLOOD
- Excellent outcome of allogeneic hematopoietic SCT with reduced-intensity conditioning for the treatment of chronic active EBV infection
- (2010) K Kawa et al. BONE MARROW TRANSPLANTATION
- Epstein‐Barr Virus–Associated Hemophagocytic Lymphohistiocytosis in Adults Characterized by High Viral Genome Load within Circulating Natural Killer Cells
- (2010) C. P. Fox et al. CLINICAL INFECTIOUS DISEASES
- CD137 ligand, a member of the tumor necrosis factor family, regulates immune responses via reverse signal transduction
- (2010) Zhe Shao et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Reporting Animal Studies: Good Science and a Duty of Care
- (2010) Catriona J. MacCallum PLOS BIOLOGY
- Mice deficient for CD137 ligand are predisposed to develop germinal center-derived B-cell lymphoma
- (2009) S. Middendorp et al. BLOOD
- Aberrant overexpression of microRNAs activate AKT signaling via down-regulation of tumor suppressors in natural killer-cell lymphoma/leukemia
- (2009) Y. Yamanaka et al. BLOOD
- Strong induction of 4-1BB, a growth and survival promoting costimulatory receptor, in HTLV-1-infected cultured and patients' T cells by the viral Tax oncoprotein
- (2008) K. Pichler et al. BLOOD
- Epstein-Barr Virus-Encoded LMP1 Regulates Epithelial Cell Motility and Invasion via the ERK-MAPK Pathway
- (2008) C. W. Dawson et al. JOURNAL OF VIROLOGY
- Identification of regulatory functions for 4-1BB and 4-1BBL in myelopoiesis and the development of dendritic cells
- (2008) Seung-Woo Lee et al. NATURE IMMUNOLOGY
- The c-Jun N-terminal kinase pathway is critical for cell transformation by the latent membrane protein 1 of Epstein–Barr virus
- (2007) Helmut Kutz et al. VIROLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More